Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.51 USD

18.51
485,115

+0.85 (4.81%)

Updated Nov 11, 2024 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA

by Zacks Equity Research

Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

by Zacks Equity Research

SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.

Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth

by Zacks Equity Research

Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 25% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

by Kinjel Shah

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

by Zacks Equity Research

Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.

Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

by Zacks Equity Research

Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.